Join        Login             Stock Quote

Ariad (ARIA) Could Be Potential Takeover Candidate For Pharma Giants

 February 16, 2012 03:17 PM

Biopharma company Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) could be a potential acquisition candidate as its strong oncology pipeline is attractive to several pharma giants.

Ariad's product pipeline includes Ponatinib, a pan BCR-ABL inhibitor in phase 2 clinical trial for applications in various hematological cancers and solid tumors; and AP26113, an anaplastic lymphoma kinase (ALK) inhibitor in preclinical studies for the treatment of various cancers.

RBC Capital Markets estimate Ponatinib is a potential $700-million franchise with a long-term opportunity to grow globally into earlier stages of use, which offers an attractive multi-year upside growth opportunity for Ariad.

[Related -Amgen, Inc. (NASDAQ:AMGN): What Will Drive Amgen This Year?]

In addition, the company's AP26113 is said to have more potential than Ponatinib and could drive further stock upside as it is expected to generate revenues in the range of $500 million to $1 billion.

"When we are asked which mid-cap companies could one day grow up to become the next "large cap" biotech, the profile of Ariad often comes to mind," RBC Capital Markets analyst Michael Yee wrote in a note to clients.

Though Incyte Corp. (NASDAQ:INCY), Seattle Genetics (NASDAQ:SGEN), and Pharmacyclics Inc. (NASDAQ:PCYC) are similar mid-cap cancer peers, Yee thinks Ariad is a more likely takeout.

[Related -Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA): Rocking and Rolling on Iclusig]

The noticeable difference is that Incyte and Pharmacyclics are partnered and thus already more "encumbered" with an existing partner on high-value drugs. Meanwhile, Seattle Genetics has attractive drugs pipeline with more modest market potential.

In contrast, Ariad is a traditional small-molecule structure-based cancer company with potential $1 billion drugs and no worldwide sales force or real global infrastructure just yet. 

Thus, it has more synergy with traditional cancer companies like Celgene Corp. (NASDAQ:CELG), Amgen, Inc. (NASDAQ:AMGN), Eli Lilly & Co. (NYSE:LLY), Merck & Co., Inc. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ).

Ariad is also attractive to European and Japanese pharma majors such as Astellas and Takeda, which are building out their oncology franchises and remain highly acquisitive.

The situation was similar when Abraxis, OSI, Cougar, ImClone, Millennium, were acquired. The potential acquirers may try to strike a deal before the stock becomes too expensive. Shares of Ariad have already surged 139 percent in the last one year. Shares of the company have soared from about $6 to $16 and market capitalization surpassed $2 billion in last one year. They ended Wednesday's regular trading session at $15.05. Yee has a price target of $20.

iOnTheMarket Premium


Comments Closed

rss feed

Latest Stories

article imageThe S&P 500’s Worrisome Downturn In Drawdown

Last Friday I reviewed some of the bearish signals that were casting dark shadows across the US stock read on...

article imageADP: Private-Sector Employment Rises A Solid 200k In September

The pace of growth for private-sector employment picked up in September, according to this morning’s ADP read on...

article imageTreasury Market’s Inflation Expectations Tumble

The odds for a Fed rate hike are falling like a stone, or so it appears based on the implied inflation read on...

article imageEmerging Market Stocks: Last Week’s Red-Ink Leader

Value investors on the lookout for bargains have recently been eyeing up the battered corner of emerging read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.